The use of renin–angiotensin–aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID‐19 patients: A systematic review and meta‐analysis
Authors:
Open Access
- 23 October 2020
- journal article
- review article
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (3) , 1370-1377
Abstract
Renin–angiotensin–aldosterone system (RAAS) inhibitors, including angiotensin‐converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are one of the most prescribed antihypertensive medications. Previous studies showed RAAS inhibitors increase the expression of ACE2, a cellular receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which provokes a concern that the use of ACEI and ARB in hypertensive individuals might lead to increased mortality and severity of coronavirus disease 2019 (COVID‐19). To further investigate the effects of ACEI/ARB on COVID‐19 patients, we systematically reviewed relevant studies that met predetermined inclusion criteria in search of PubMed, Embase, Cochrane Library databases, medRxiv, and bioRxiv. The search strategy included clinical data published through October 12, 2020. Twenty‐six studies involving 8104 hypertensive patients in ACEI/ARB‐treated group and 8203 hypertensive patients in non‐ACEI/ARB‐treated group were analyzed. Random‐effects meta‐analysis showed ACEI/ARB treatment was significantly associated with a lower risk of mortality in hypertensive COVID‐19 patients (odds ratio [OR] = 0.624, 95% confidence interval [CI] = 0.457–0.852, p = .003, I2 = 74.3%). Meta‐regression analysis showed that age, gender, study site, Newcastle–Ottawa Scale scores, comorbidities of diabetes, coronary artery disease, chronic kidney disease, or cancer has no significant modulating effect of ACEI/ARB treatment on the mortality of hypertensive COVID‐19 patients (all p > .1). In addition, the ACEI/ARB treatment was associated with a lower risk of ventilatory support (OR = 0.682, 95% CI = 0.475–1.978, p = .037, I2 = 0.0%). In conclusion, these results suggest that ACEI/ARB medications should not be discontinued for hypertensive patients in the context of COVID‐19 pandemic.Keywords
Funding Information
- National Natural Science Foundation of China (82072292)
- Natural Science Foundation of Guangdong Province (2018A030307061)
- Department of Education of Guangdong Province (2017KTSCX067, 2020KZDZX1084)
This publication has 40 references indexed in Scilit:
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Electroacupuncture Improved Chronic Cerebral Hypoperfusion-Induced Anxiety-Like Behavior and Memory Impairments in Spontaneously Hypertensive Rats by Downregulating the ACE/Ang II/AT1R Axis and Upregulating the ACE2/Ang-(1-7)/MasR AxisNeural Plasticity, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1–7)-Mas axes in pressure overload-induced cardiac remodeling in male miceJournal of Molecular and Cellular Cardiology, 2016
- Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitorsAmino Acids, 2014
- Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor–Dependent MechanismHypertension, 2014
- Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and DiseaseInternational Journal of Peptides, 2012
- Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartanAmerican Journal of Physiology-Renal Physiology, 2009
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004